Aug 1 (Reuters) - Evaxion Biotech A/S EVAX.O :
* EVAXION ANNOUNCES FINANCING COMMITMENTS TOTALING UP TO USD
20
MILLION WITH NEGMA GROUP
* EVAXION BIOTECH A/S - FINANCING, AVAILABLE IN MULTIPLE
TRANCHES
OVER NEXT THREE YEARS, COULD EXTEND COMPANY'S RUNWAY INTO Q4
2024
* EVAXION BIOTECH A/S - TRANSACTION WILL ENABLE EVAXION TO
ADVANCE
ITS NEXT-GENERATION CANCER VACCINE, EVX-03, TOWARDS A PHASE 1
CLINICAL TRIAL
Source text for Eikon: ID:nGNX6wLJKv
Further company coverage: EVAX.O
((Reuters.Briefs@thomsonreuters.com;))